Modern Russian pharmaceutical drugs for treatment of neurological diseases

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Neurodegenerative diseases are characterized by progressive loss of specific types of nerve cells, accompanied by atrophy of corresponding regions of the spinal cord or brain, which clinically manifests as severe neurological and cognitive impairments. These diseases can present at any age and may be associated with genetic predisposition, as well as inflammatory and autoimmune processes. Neurodegenerative diseases are a common cause of disability and mortality among affected patients. Thus, the development of new effective domestic drugs for the treatment of neuropathology is a significant objective for the healthcare system of the Russian Federation. The majority of these are biosimilar drugs reproducing pharmacological substances of foreign (donepezil+memantine, ANB-4, GNR-093) and Russian (interferon beta-b) origin. However, original pharmaceutical substances have also been developed. Three of these, ANB-4, divosilimumab, and sampheginterferon beta-a, are classified as next-in-class drugs. This review article analyzes original and biosimilar organic and genetically engineered pharmaceutical drugs developed in Russia for the treatment of neurodegenerative diseases, which have either been registered in recent years or are currently undergoing clinical trials in the Russian Federation. The development of effective and safe Russian pharmaceutical agents for the treatment of neuropathology may increase the accessibility of therapy for a larger number of patients, significantly improve their health and quality of life, as well as reduce the burden on the healthcare system.

Full Text

Restricted Access

About the authors

Elena V. Galitsyna

Russian Research Institute of Health

Author for correspondence.
Email: galitsynaev@mednet.ru
ORCID iD: 0000-0003-2305-4936
SPIN-code: 2751-1747

Cand. Sci. (Biology)

Russian Federation, Moscow

Natalya A. Ulyakina

Russian Research Institute of Health

Email: ulyakinana@mednet.ru
ORCID iD: 0000-0003-0187-1898
SPIN-code: 4361-1951

Cand. Sci. (Pedagogy)

Russian Federation, Moscow

Alexander B. Gusev

Russian Research Institute of Health

Email: gusevab@mednet.ru
ORCID iD: 0000-0001-9063-0601
SPIN-code: 4004-6894

Cand. Sci. (Economics)

Moscow

References

  1. Davenport F, Gallacher J, Kourtzi Z, et al. Neurodegenerative disease of the brain: a survey of interdisciplinary approaches. J R Soc Interface. 2023;20(198):20220406. doi: 10.1098/rsif.2022.0406
  2. Yusupov FA, Yuldashev AA. Biomarkers of neurodegenerative diseases. Bulletin of Science and Practice. 2021;7(9):341–352. doi: 10.33619/2414-2948/70/30 EDN: RTUTTI
  3. Neganova ME, Aleksandrova YR, Nebogatikov VO, et al. Promising molecular targets for pharmacological therapy of neurodegenerative pathologies. Acta Naturae (Russian Version). 2020;12(3):60–80. doi: 10.32607/actanaturae.10925 EDN: ZCZGOV
  4. Melnikova EV, Merkulov VA, Merkulova OV. Gene therapy of neurodegenerative diseases: achievements, developments, and clinical implementation challenges. Biological products. Prevention, diagnosis, treatment. 2023;23(2):127–147. doi: 10.30895/2221-996X-2023-433 EDN: DNBPXQ
  5. Chaplenko AA, Vlasov VV, Gildeeva GN. Innovative medicines on the Russian pharmaceutical market: key players and main directions of development. Remedium. 2020;(10):4–9. doi: 10.21518/1561-5936-2020-10-4-9 EDN: ZIVVJC
  6. Li Y, Zeng H, Wei Y, et al. An overview of the therapeutic strategies for the treatment of spinal muscular atrophy. Hum Gene Ther. 2023;34(5–6):180–191. doi: 10.1089/hum.2022.189 EDN: RSFMHU
  7. Angilletta I, Ferrante R, Giansante R, et al. Spinal muscular atrophy: an evolving scenario through new perspectives in diagnosis and advances in therapies. Int J Mol Sci. 2023;24(19):14873. doi: 10.3390/ijms241914873 EDN: BTXHVV
  8. Kumar A, Sidhu J, Lui F, et al. Alzheimer Disease. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499922/
  9. Dubois B, Villain N, Frisoni GB, et al. Clinical diagnosis of Alzheimer’s disease: recommendations of the International Working Group. Lancet Neurol. 2021;20(6):484–496. doi: 10.1016/S1474-4422(21)00066-1 EDN: SIIFOM
  10. Chau S, Herrmann N, Ruthirakuhan MT, et al. Latrepirdine for Alzheimer’s disease. Cochrane Database Syst Rev. 2015;2015(4): CD009524. doi: 10.1002/14651858.CD009524.pub2 EDN: YDHGRV
  11. Bachurin SO. A review of drugs for treatment of Alzheimer’s disease in clinical trials: main trends. S.S. Korsakov journal of neurology and psychiatry. 2016;116(8):77–87. doi: 10.17116/jnevro20161168177-87 EDN: WKFNAT
  12. Govorushkina NS, Bolevich SB, Yakovlevich V, et al. The influence of MK-801, glutamate and glycine via the modulation of N-methyl-D-aspartate receptors on isolated rat heart. Sechenov medical journal. 2020;11(1):15–25. doi: 10.47093/2218-7332.2020.11.1.15-25 EDN: TQQOFO
  13. Kuns B, Rosani A, Patel P, et al. Memantine. [Updated 2024 Jan 31]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK500025/
  14. Guo J, Wang Z, Liu R, et al. Memantine, donepezil, or combination therapy-what is the best therapy for Alzheimer’s disease? A network meta-analysis. Brain Behav. 2020;10(11):e01831. doi: 10.1002/brb3.1831 EDN: VVZFZB
  15. Smolyarchuk EA, Leykin ZN. Comparative clinical study of the pharmacokinetics and bioequivalence of the combined drug mioreol and the combined use of mono-drugs containing donepezil and memantine. S.S. Korsakov journal of neurology and psychiatry. 2022;122(3):85–91. doi: 10.17116/jnevro202212203185 EDN: PVUNZK
  16. Fleet JL, McArthur E, Patel A, et al. Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study. CMAJ. 2019;191(37):E1018–E1024. doi: 10.1503/cmaj.190337
  17. Lermontova NN, Lukoyanov NV, Serkova TP, et al. Dimebon improves learning in animals with experimental Alzheimer’s disease. Bull Exp Biol Med. 2020;129(6):544–546. doi: 10.1007/BF02434871 EDN: LGBSPD
  18. Bachurin S, Bukatina E, Lermontova N, et al. Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann N Y Acad Sci. 2001;939:425–435. doi: 10.1111/j.1749-6632.2001.tb03654.x EDN: LGTBGB
  19. Sabbagh MN, Shill HA. Latrepirdine, a potential novel treatment for Alzheimer’s disease and Huntington’s chorea. Curr Opin Investig Drugs. 2010;11(1):80–91. EDN: MXXCZT
  20. Ivachtchenko AV, Lavrovsky Y, Okun I. AVN-101: a multi-target drug candidate for the treatment of CNS disorders. J Alzheimers Dis. 2016;53(2):583–620. doi: 10.3233/JAD-151146 EDN: WRZEEH
  21. Клинические рекомендации. Рассеянный склероз. 2022 г. Режим доступа: https://cr.minzdrav.gov.ru/schema/739_1. Дата обращения: 19.08.2024.
  22. Boyko AN. Selecting the best treatment for multiple sclerosis. Medical Council. 2015;(5):78–79. EDN: TVYXVB
  23. Avksentiev NA, Davydovskaya MV, Makarova YV, et al. Pharmacoeconomic aspects of using cladribine (in tablets) for treatment of adult patients with remitting multiple sclerosis. S.S. Korsakov journal of neurology and psychiatry. 2021;121(8):30–36. doi: 10.17116/jnevro202112108130 EDN: FUAAKB
  24. Palmer AM. Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis. Curr Opin Investig Drugs. 2010;11(11):1313–1323.
  25. Rabie AM. Teriflunomide: a possible effective drug for the comprehensive treatment of COVID-19. Curr Res Pharmacol Drug Discov. 2021;2:100055. doi: 10.1016/j.crphar.2021.100055 EDN: NASMUY
  26. Li Z, Chen X, Chen Y, et al. Teriflunomide suppresses T helper cells and dendritic cells to alleviate experimental autoimmune uveitis. Biochem Pharmacol. 2019;170:113645. doi: 10.1016/j.bcp.2019.113645
  27. Cencioni MT, Mattoscio M, Magliozzi R, et al. B cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies. Nat Rev Neurol. 2021;17(7):399–414. doi: 10.1038/s41582-021-00498-5 EDN: KEVUPT
  28. Comi G, Bar-Or A, Lassmann H, et al. Role of B cells in multiple sclerosis and related disorders. Ann Neurol. 2021;89(1):13–23. doi: 10.1002/ana.25927 EDN: ORSJOO
  29. Boyko AN, Alifirova VM, Lukashevich IG, et al. Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS. S.S. Korsakov journal of neurology and psychiatry. 2024;124(4):86–96. doi: 10.17116/jnevro202412404186 EDN: FGQVJM
  30. Zafar S, Yaddanapudi SS. Parkinson Disease. [Updated 2023 Aug 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470193/
  31. Vorontkov DN, Salkov VN, Anufriev PL, et al. Lewy bodies in Parkinson’s disease: histological, immunohistochemical, and interferometric examinations. Russian Journal of Archive of Patology. 2018;80(4):9–13. doi: 10.17116/patol20188049 EDN: XULSZN
  32. Han TU, Sam R, Sidransky E. Small molecule chaperones for the treatment of Gaucher disease and GBA1-associated Parkinson disease. Front Cell Dev Biol. 2020;8:271. doi: 10.3389/fcell.2020.00271 EDN: XTFCQP
  33. Abramovich RA, Potanina OG, Alsharida Z, et al. Direct effect of acetylcholine on Parkinson’s disease. International Journal of Medicine and Psychology. 2020;3(6):113–121. EDN: MKIGSW
  34. Sogo K, Sogo M, Okawa Y. Centrally acting anticholinergic drug trihexyphenidyl reduces nightmares in PTSD. Brain Behav. 2021;11(6): e02147. doi: 10.1002/brb3.2147 EDN: ZQBXXE
  35. Tolstikova TG, Pavlova AV, Morozova YA, et al. A novel antiparkinsonian drug. Dokl Biol Sci. 2010;435:398–399. doi: 10.1134/S0012496610060074 EDN: OAAXED
  36. Kotliarova A, Podturkina AV, Pavlova AV, et al. A monoterpenoid-based small molecule protects dopamine neurons and alleviates MPTP toxicity. Molecules. 2022;27(23):8286. doi: 10.3390/molecules27238286 EDN: OUENOR

Copyright (c) 2025 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 65565 от 04.05.2016 г.